News

TB R&D Weekly Update: Podcast Interview with Eric Nuermberger

Listen to Eric Nuermberger Podcast


Summary: Dr. Eric Nuermberger is Associate Professor of Medicine in the Division of Infectious Diseases, Department of Medicine, at Johns Hopkins University School of Medicine. The WGND had the opportunity to talk with Dr. Nuermberger on a recent article entitled “PA-824 exhibits time-dependent activity in a murine model of tuberculosis” that we covered in a previous TB R&D Weekly Update. The article is published in Antimicrobial Agents and Chemotherapy in January 2011. In the interview, Dr. Nuermberger provides an overview of his present research, key results presented in the article, and in vitro and preclinical testing of TB drug regimens.

Additional TB R&D News:

U.S. Bioethics Panel to Review Clinical Trials Around the World

Investing in the drug pipeline

Moxifloxacin and pyrazinamide susceptibility testing in a complex case of multidrug-resistant tuberculosis

Research frontlines: Christenson speaks to advancing global health technologies

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...